ATAI LIFE SCIENCES N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.85 USD | -3.14% |
|
-19.57% | +31.21% |
Presenter SpeechSrinivas Rao (Executives)Good morning, everybody, and welcome to Atai's webina...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.91
USD
Average target price
11.8
USD
Spread / Average Target
+517.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.21% | 317M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- ATAI Stock
- News Atai Life Sciences N.V.
- Transcript : Atai Life Sciences N.V. - Special Call
